Literature DB >> 21323797

Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination.

Y-Y Luo1, G-S Zhang.   

Abstract

Acquired factor XIII (FXIII) deficiency, arising from an autoantibody against factor XIII, is a rare bleeding disorder. This autoimmune disorder most commonly occurs in the elderly. Patients who develop such acquired FXIII inhibitors may present with catastrophic bleeding events and are hard to be diagnosed with the normal general coagulation tests. Though the disease is relatively rare, it is known to cause significant mortality. In this article we briefly describe a patient who presented with extensive bleeding and a normal activated partial thromboplastin time and prothrombin time (PT), but had an acquired inhibitor to FXIII; her primary disease was systemic lupus erythematosus (SLE). Also, we will focus on the clinical features, treatment modalities, fibrin structure and epitope identification for acquired factor XIII inhibitor with a review of the literature.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21323797     DOI: 10.1111/j.1365-2516.2010.02459.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  4 in total

Review 1.  Acquired FXIII inhibitors: a systematic review.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

2.  Life-threatening retro-pharyngeal bleed in a case of systemic lupus erythematosus--an uncommon but important evil of a common disease.

Authors:  Amruth Palla; John Rogers; Sindhu Singh
Journal:  BMJ Case Rep       Date:  2011-10-11

3.  New developments in the management of congenital Factor XIII deficiency.

Authors:  Zehra Fadoo; Quratulain Merchant; Karim Abdur Rehman
Journal:  J Blood Med       Date:  2013-05-28

4.  Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.

Authors:  Sho Mokuda; Yosuke Murata; Naoya Sawada; Kenichiro Matoba; Akihiro Yamada; Makoto Onishi; Yasuaki Okuda; Kazuo Jouyama; Eiji Sugiyama; Kiyoshi Takasugi
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.